GeneDx Holdings Corp. faces a class action lawsuit alleging it misled investors about the viability of Fabric Genomics, a company it acquired. The lawsuit claims GeneDx and executives made false statements and failed to disclose problems that hurt business, leading to a 49% stock drop after poor Q1 2026 results were announced. Investors who bought GeneDx stock between April 16, 2025, and May 4, 2026, can apply to be lead plaintiff by August 3, 2026. The lead plaintiff will represent all class members in the case, potentially influencing the litigation's direction and recovery efforts.
GeneDx Holdings Corp. shares dropped 49% on May 5, 2025, after the company reported a massive tenfold increase in net loss for Q1 2026 and cut its full-year 2026 revenue guidance by 12%. The company’s average reimbursement rate fell short due to a sh...
A class action lawsuit has been filed against GeneDx Holdings Corp. and some of its officers for allegedly misleading investors between April 16, 2025, and May 4, 2026. The complaint claims the company made false statements and failed to disclose key...
GeneDx Holdings Corp. shares fell over 49% after the company reported weaker-than-expected Q1 results and lowered its 2026 revenue guidance from $540-555 million to $475-490 million. The company also revealed a $31.3 million goodwill impairment relat...
